Eli Lilly's Mounjaro Added to China's National Health Insurance for Diabetes

Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term.

Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move could increase pressure on rival companies.

Being included in the national reimbursement list makes a drug more accessible to China’s 1.4 billion population. However, while sales volume may rise, lower prices often offset some of the revenue gains.

Mounjaro, a once-weekly injectable therapy, was launched in China in January this year, following the introduction of Ozempic, a similar diabetes treatment from Danish rival Novo Nordisk. Eli Lilly and Company (NYSE:LLY) said the final reimbursement prices for Mounjaro will be determined by the National Healthcare Security Administration’s official announcement. The NHSA did not immediately respond to requests for pricing details.

Eli Lilly and Company (NYSE:LLY) is a major American pharmaceutical company that develops medicines and treatments for serious conditions.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 11 Worst Performing Dividend Stocks Year-to-Date.

Disclosure: None.